MX2019009554A - Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral. - Google Patents
Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral.Info
- Publication number
- MX2019009554A MX2019009554A MX2019009554A MX2019009554A MX2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A MX 2019009554 A MX2019009554 A MX 2019009554A
- Authority
- MX
- Mexico
- Prior art keywords
- necrotic enteritis
- egg product
- clostridium perfringens
- poultry
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En un aspecto, la presente invención se dirige a un método para prevenir o tratar la enteritis necrótica administrando un producto de huevo hiperinmunizado obtenido de un animal productor de huevo a un ave. El producto de huevo hiperinmunizado puede contener un anticuerpo específico para un antígeno seleccionado del grupo que consiste de toxina a de Clostridium perfringens, factor de elongación Tu (EF-Tu) de Clostridium perfringens, toxina tipo B de enteritis necrótica (NetB) de Clostridium perfringens, piruvato:oxidorreductasa de Ferredoxina (PFO) de Clostridium perfringens y factor de elongación 1-alfa de Eimeria tenella.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762458180P | 2017-02-13 | 2017-02-13 | |
US201762568932P | 2017-10-06 | 2017-10-06 | |
PCT/US2018/018015 WO2018148734A1 (en) | 2017-02-13 | 2018-02-13 | Hyperimmunized egg product for treatment of necrotic enteritis in poultry |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019009554A true MX2019009554A (es) | 2020-01-30 |
Family
ID=63106738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009554A MX2019009554A (es) | 2017-02-13 | 2018-02-13 | Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral. |
Country Status (5)
Country | Link |
---|---|
US (2) | US10450364B2 (es) |
BR (1) | BR112019016642A2 (es) |
CA (1) | CA3053150A1 (es) |
MX (1) | MX2019009554A (es) |
WO (1) | WO2018148734A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10450364B2 (en) | 2017-02-13 | 2019-10-22 | Arkion Life Sciences, Llc | Hyperimmunized egg product for treatment of necrotic enteritis in poultry |
CN109187964A (zh) * | 2018-09-06 | 2019-01-11 | 湖北省农业科学院畜牧兽医研究所 | 一种利用一枚种蛋对禽白血病和鸡沙门氏菌病同时净化检测的方法及其应用 |
EP3919073B1 (en) * | 2020-06-05 | 2024-05-15 | Schweitzer Biotech Company Ltd. | Composition for preventing infestation and infection of sea lice on salmon |
CN112841133B (zh) * | 2021-02-01 | 2022-04-05 | 四川农业大学 | 一种蛋鸡小肠肠炎模型的构建方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
DE69737191T2 (de) | 1996-03-26 | 2007-11-08 | Arkion Life Sciences Llc., Wilmington | Entzündungshemmende Zusammensetzung aus Ei, Verfahren zur Isolierung und Verwendung |
US5772999A (en) | 1996-07-30 | 1998-06-30 | Dcv Biologics, L.P. | Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals |
US6803035B2 (en) | 1998-05-08 | 2004-10-12 | Arkion Life Sciences | Anti-diarrheal and method for using the same |
AU2372400A (en) | 1999-01-19 | 2000-08-07 | Dcv, Inc. | Egg anti-inflammatory composition and method of treating and preventing inflammation |
CN1376163A (zh) | 1999-07-23 | 2002-10-23 | Dcv公司 | 高度纯化的细胞因子激活因子和使用方法 |
US6706267B1 (en) | 1999-09-14 | 2004-03-16 | Arkion Life Sciences Llc | Glucosamine and egg for reducing inflammation |
KR20040105710A (ko) | 2002-02-11 | 2004-12-16 | 아르키온 라이프 사이언씨즈 엘엘씨 | 정제된 사이토킨 억제인자 |
JP3995541B2 (ja) * | 2002-06-28 | 2007-10-24 | 株式会社ゲン・コーポレーション | 抗鶏コクシジウム症組成物 |
US20110020356A1 (en) | 2007-12-07 | 2011-01-27 | Lin Fang | Therapeutic clostridium difficile antibody compositions |
US10450364B2 (en) | 2017-02-13 | 2019-10-22 | Arkion Life Sciences, Llc | Hyperimmunized egg product for treatment of necrotic enteritis in poultry |
-
2018
- 2018-02-13 US US15/895,636 patent/US10450364B2/en active Active
- 2018-02-13 CA CA3053150A patent/CA3053150A1/en active Pending
- 2018-02-13 WO PCT/US2018/018015 patent/WO2018148734A1/en active Application Filing
- 2018-02-13 BR BR112019016642-4A patent/BR112019016642A2/pt unknown
- 2018-02-13 MX MX2019009554A patent/MX2019009554A/es unknown
-
2019
- 2019-09-18 US US16/574,954 patent/US11230590B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112019016642A2 (pt) | 2020-03-31 |
US20200002404A1 (en) | 2020-01-02 |
CA3053150A1 (en) | 2018-08-16 |
US11230590B2 (en) | 2022-01-25 |
US20180230199A1 (en) | 2018-08-16 |
WO2018148734A1 (en) | 2018-08-16 |
US10450364B2 (en) | 2019-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019009554A (es) | Producto de huevo hiperinmunizado para el tratamiento de enteritis necrotica en aves de corral. | |
BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
EA201991157A1 (ru) | Доставка белков на основе бактерий, аттенуированных по вирулентности | |
BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
BR112015026258A2 (pt) | composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos | |
BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
EA201892190A1 (ru) | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы | |
AR121361A1 (es) | Vacuna | |
BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
MX2020010269A (es) | Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. | |
CO2020000260A2 (es) | Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide | |
BR112021021649A2 (pt) | Composições farmacêuticas injetáveis e usos das mesmas | |
CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
BR112019011350A2 (pt) | terapia de combinação | |
BR112015009306A2 (pt) | Anticorpos anti-campylobacter jejuni e usos dos mesmos | |
EP4252847A3 (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
BR112016023011A2 (pt) | tratamento de câncer gástrico | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
BR112022004302A2 (pt) | Anticorpos anti-il-27 e usos dos mesmos | |
BR112021004464A8 (pt) | composição de ração animal e uso da mesma | |
BR112021017710A2 (pt) | Composto, composição farmacêutica, método de tratamento | |
MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. | |
BR112019005217A2 (pt) | terapia combinada | |
CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen |